{"id":"vaccin-genhevac-b-pasteur","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain or swelling"},{"rate":"1-6","effect":"Fever"},{"rate":"1-5","effect":"Fatigue"},{"rate":"1-5","effect":"Headache"},{"rate":"1-3","effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains hepatitis B surface antigen produced through recombinant DNA technology. Upon administration, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies (anti-HBs) and memory B cells. This immunological memory enables rapid immune response upon exposure to the actual hepatitis B virus, preventing infection and disease development.","oneSentence":"GenHevac B Pasteur is a hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:41.702Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection in infants, children, and adults"}]},"trialDetails":[{"nctId":"NCT01698866","phase":"PHASE4","title":"Low Grade Lymphoma","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2012-07","conditions":"Indolent Lymphoproliferative Disorders","enrollment":40},{"nctId":"NCT00670839","phase":"PHASE3","title":"Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2008-05","conditions":"Hepatitis B, HIV Infection","enrollment":178},{"nctId":"NCT00480792","phase":"PHASE3","title":"Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2007-06","conditions":"HIV Infections","enrollment":437}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"MULTIPLE SCLEROSIS"},{"count":1,"reaction":"ANTIBODY TEST POSITIVE"},{"count":1,"reaction":"MYOFASCITIS"},{"count":1,"reaction":"SUBARACHNOID HAEMORRHAGE"},{"count":1,"reaction":"TRISMUS"},{"count":1,"reaction":"UPPER MOTOR NEURONE LESION"},{"count":1,"reaction":"WEIGHT DECREASED"}],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Vaccin GenHevac B Pasteur","genericName":"Vaccin GenHevac B Pasteur","companyName":"Central Hospital, Nancy, France","companyId":"central-hospital-nancy-france","modality":"Biologic","firstApprovalDate":"","aiSummary":"GenHevac B Pasteur is a hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen (HBsAg), providing protection against hepatitis B virus infection. Used for Prevention of hepatitis B infection in infants, children, and adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}